Epigenetics in the diagnosis and prognosis of head and neck cancer: A systematic review

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-02-05 DOI:10.1111/jop.13513

Isaac Lim, Jade Tan, Anneka Alam, Majdy Idrees, Peter A. Brenan, Ricardo Della Coletta, Omar Kujan

{"title":"Epigenetics in the diagnosis and prognosis of head and neck cancer: A systematic review","authors":"Isaac Lim, Jade Tan, Anneka Alam, Majdy Idrees, Peter A. Brenan, Ricardo Della Coletta, Omar Kujan","doi":"10.1111/jop.13513","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Aberrant epigenetic modifications significantly develop and progress human malignancies including head and neck squamous cell carcinoma (HNSCC). Taking into account issues of late diagnosis and poor prognosis associated with HNSCC, this systematic review is designed to provide an up-to-date insight of epigenetic changes in the management of HNSCC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>All studies that assessed the diagnostic and prognostic utilities of epigenetic changes (DNA methylation and histone modifications) among patients diagnosed with HNSCC or oral potentially malignant disorders (OPMDs) were considered for inclusion till June 2023. Pre-defined Medical Subject Headings terms were used to search Web of Science, Pubmed, Scopus and Embase Ovid databases.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Twenty-five studies were deemed eligible for inclusion with a total number of 3790 samples (2123 HNSCCs, 334 OPMDs and 1333 as controls). DNA methylation was investigated in 18 studies while the role of histone modifications was assessed in seven studies. The most investigated biomarkers among the studies were H3, DAPK and TIMP3. The diagnostic accuracy of the epigenetic biomarkers in detecting HNSCC was assessed in eight studies where the following biomarkers showed the highest area under the curve values: TIPM3, DCC, DAPK, SEPT9, SHOX9, HOXA9 and TRH. None of the studies assessed the predictability of the epigenetic biomarkers in HNSCC and OPMDs.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Although initial promising results were seen using the epigenetic biomarkers in the early detection of HNSCC, the limited number of patients and the absence of well-designed longitudinal studies limit the clinical applicability of the outcomes.</p>\n </section>\n </div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jop.13513","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jop.13513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Aberrant epigenetic modifications significantly develop and progress human malignancies including head and neck squamous cell carcinoma (HNSCC). Taking into account issues of late diagnosis and poor prognosis associated with HNSCC, this systematic review is designed to provide an up-to-date insight of epigenetic changes in the management of HNSCC.

Methods

All studies that assessed the diagnostic and prognostic utilities of epigenetic changes (DNA methylation and histone modifications) among patients diagnosed with HNSCC or oral potentially malignant disorders (OPMDs) were considered for inclusion till June 2023. Pre-defined Medical Subject Headings terms were used to search Web of Science, Pubmed, Scopus and Embase Ovid databases.

Results

Twenty-five studies were deemed eligible for inclusion with a total number of 3790 samples (2123 HNSCCs, 334 OPMDs and 1333 as controls). DNA methylation was investigated in 18 studies while the role of histone modifications was assessed in seven studies. The most investigated biomarkers among the studies were H3, DAPK and TIMP3. The diagnostic accuracy of the epigenetic biomarkers in detecting HNSCC was assessed in eight studies where the following biomarkers showed the highest area under the curve values: TIPM3, DCC, DAPK, SEPT9, SHOX9, HOXA9 and TRH. None of the studies assessed the predictability of the epigenetic biomarkers in HNSCC and OPMDs.

Conclusion

Although initial promising results were seen using the epigenetic biomarkers in the early detection of HNSCC, the limited number of patients and the absence of well-designed longitudinal studies limit the clinical applicability of the outcomes.

Abstract Image

查看原文本刊更多论文

头颈癌诊断和预后中的表观遗传学：系统综述。

背景：表观遗传学的异常改变对包括头颈部鳞状细胞癌（HNSCC）在内的人类恶性肿瘤的发生和发展具有重要意义。考虑到与 HNSCC 相关的晚期诊断和不良预后问题，本系统综述旨在提供有关 HNSCC 治疗中表观遗传学变化的最新见解：截至 2023 年 6 月，所有评估确诊为 HNSCC 或口腔潜在恶性疾病 (OPMD) 患者的表观遗传学变化（DNA 甲基化和组蛋白修饰）的诊断和预后效用的研究均被纳入考虑范围。使用预先定义的医学主题词搜索 Web of Science、Pubmed、Scopus 和 Embase Ovid 数据库：25项研究被认为符合纳入条件，样本总数为3790个（2123个HNSCC、334个OPMD和1333个对照）。18项研究对DNA甲基化进行了调查，7项研究对组蛋白修饰的作用进行了评估。这些研究中调查最多的生物标志物是 H3、DAPK 和 TIMP3。八项研究评估了表观遗传生物标志物在检测 HNSCC 方面的诊断准确性，其中以下生物标志物的曲线下面积值最高：TIPM3、DCC、DAPK、SEPT9、SHOX9、HOXA9 和 TRH。没有一项研究评估了表观遗传生物标志物在 HNSCC 和 OPMD 中的可预测性：尽管利用表观遗传生物标记物早期检测 HNSCC 取得了初步的可喜成果，但由于患者人数有限且缺乏设计良好的纵向研究，这些结果的临床适用性受到了限制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464